Cost-effectiveness of psoriasis therapy with etanercept in Germany

@inproceedings{DanielDHeinenKammerer2017CosteffectivenessOP,
  title={Cost-effectiveness of psoriasis therapy with etanercept in Germany},
  author={T DanielDHeinen-Kammerer and L RychlikRStratmann and H BoehnckeW},
  year={2017}
}
  • Daniel D Heinen - Kammerer T, Rychlik R Stratmann L, H BoehnckeW
  • Published 2017
Study population The study population comprised a hypothetical cohort of patients with moderate-to-severe psoriasis. Three sub-groups of patients were considered on the basis of disease severity, as represented by two scores, the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI). The three sub-groups were PASI and DLQI greater than 10, PASI and DLQI greater than 15, and PASI and DLQI greater than 20.